Jerry Bagel MD MS, Brianna Butler MS PA-C, Elise Nelson LPN CCRC, Alexa Hetzel MS PA-C
Biologic treatments have taken the forefront in treating moderate-to-severe psoriasis. Although numerous randomized, controlled trials have demonstrated the efficacy of these agents, there is limited data suggesting that clinical trial outcomes are reproducible in real-world patients. J Drugs Dermatol. 20(4):442-449. doi:10.36849/JDD.2021.5823 Read more.
Donovan G. Kearns, Shelley Uppal PhD, Vipawee S. Chat, Jashin J. Wu MD
As the COVID-19 pandemic persists globally, physicians continue to assess the safety and benefit of immunomodulatory medications, in order to reduce the risk of infection or worsened disease outcomes in patients. While there is emerging evidence that targeted immunosuppression may be helpful in cases of severe COVID-19 infection with cytokine storm, this effect cannot be generalized to all immunomodulatory medications. J Drugs Dermatol. 2021;20(05):582
Once-Daily Novel Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants
Seemal R. Desai MD, Brad Glick DO MPH, James Q. Del Rosso DO, Susan Harris MS, Abby Jacobson MS PA-C
Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various racial and ethnic groups. Two phase 3 studies demonstrated efficacy and safety of a novel 0.01% lotion in the treatment of moderate-to-severe plaque psoriasis (NCT02514577, NCT02515097). These post hoc analyses evaluated HP 0.01% lotion in Hispanic participants. J Drugs Dermatol. 20(3):252-258. doi:10.36849/JDD.2021.5698
Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new development in the field. Among study comparators, the 308nm excimer laser is safe and delivers incremental clinical benefits with the potential for significant cost savings. J Drugs Dermatol. 2020;19(11):1101-1108. doi:10.36849/JDD.2020.5510
Leon H. Kircik MD, Todd E. Schlesinger MD FAAD, Emil Tanghetti MD
In the treatment of moderate plaque psoriasis, Cal/BD foam plus an oral PDE4 provided more benefits than the PDE4 alone. These improvements appeared to be lost when Cal/BD foam was withdrawn but recovered when Cal/BD foam was reinitiated. J Drugs Dermatol. 2020;19(9):874-880. doi:10.36849/JDD.2020.5020
Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement
Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD
The relationship between the clearance of psoriasis and improved quality of life together with an increased uptake of cosmetic procedures has not been reported to date. A survey was conducted to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance. J Drugs Dermatol. 2020;19(8): doi:10.36849/JDD.2020.5104R1
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis
Phoebe Rich MD, Orin Goldblum MD, Damon Disch PhD, Chen-Yen Lin PhDb, Joseph F. Merola MD, Boni Elewski MD
Presence of nail psoriasis in patients with plaque psoriasis may be an indicator of greater disease severity. Previously, patients with nail psoriasis have had delayed skin clearance after treatment compared to patients without nail psoriasis. This post-hoc analysis evaluated the efficacy of ixekizumab in clearance of plaque psoriasis in patients with and without nail psoriasis. J Drugs Dermatol. 2020;19(8):741-746. doi:10.36849/JDD.2020.5116
Leon H. Kircik MD
Newer biologics have introduced the possibility of higher and more complete clearance rates than previously possible. For many patients, PASI 90 and PASI 100 responses are realistic. Furthermore, higher levels of clearance, particularly total clearance, is associated with marked improvements in quality of life. Little data is available on the clinical benefits of higher clearance levels and how this might relate to improvements in other comorbidities. Is it time for dermatologists to strive for total clearance for our patients? J Drugs Dermatol. 2020;19(6): doi:10.36849/JDD.2020.4975
Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis
William Abramovits MD, Joel Schlessinger MD
This narrative review discusses the efficacy and safety of systemic treatments for skin and joint manifestations in patients with psoriasis to provide dermatologists and rheumatologists with an updated summary of the benefits and risks of currently available treatments on several disease domains. J Drugs Dermatol. 2020;19(3): doi:10.36849/JDD.2020.4690
We are fortunate to live during a time when we have many safe and effective options to treat a chronic inflammatory skin disease such as Psoriasis. How does clinical trial efficacy and long term use translate to the real world and practical issues such as access, patient and practitioner perception? In a JDD Podcast, two investigators share their work and first steps to evaluate.
To Treat or Not To Treat: Systemic Therapy Considerations for Psoriasis in the Setting of Malignancy
In most phase 3 studies patients are weeded out or the history of malignancy must be at least 5 years prior to entry. So what to do? Our colleagues at Tufts Medical Center asked this very question. Tune in to hear what Dr. David Rosmarin learned from performing a retrospective chart review and how his work and his experience guides his clinical decision making when managing psoriasis.
Ask the Investigator: Shedding Some Light on Phototherapy Protocols for Psoriasis and Tips to Improve Patient Screening and Treatment
Dr. Adam Friedman reviews phototherapy protocols and pearls with psoriasis expert Dr. Jashin Wu. Also tune in to hear how Dr. Wu counsels his psoriasis patients on psoriasis comorbidities and initiates, and manages them with phototherapy, topicals, and systemic immunosuppressants.
Translational Lecture Series
Dr. Jon Zippin elucidates the complexity of cAMP biology and the translational impact of PDE4 inhibition as it relates to chronic inflammatory skin diseases. Tune in to learn why targeting this pathway is clinically meaningful but also where more work is needed to improve outcomes.
Dr. Abrar Qureshi, Professor and Chair of Department of Dermatology at The Warren Alpert Medical School of Brown University, reviews his research to uncover the biological basis for many of the co-morbidities associated with, and risk factors for, psoriasis. Through this clear and clinically oriented presentation, the common pathophysiological threads are elucidated with a focus on identifying preventive strategies and therapeutic targets for current and future treatments.